Literature DB >> 11438610

Functional interaction between opioid and cannabinoid receptors in drug self-administration.

M Navarro1, M R Carrera, W Fratta, O Valverde, G Cossu, L Fattore, J A Chowen, R Gomez, I del Arco, M A Villanua, R Maldonado, G F Koob, F Rodriguez de Fonseca.   

Abstract

The present study was designed to explore the relationship between the cannabinoid and opioid receptors in animal models of opioid-induced reinforcement. The acute administration of SR141716A, a selective central cannabinoid CB1 receptor antagonist, blocked heroin self-administration in rats, as well as morphine-induced place preference and morphine self-administration in mice. Morphine-dependent animals injected with SR141716A exhibited a partial opiate-like withdrawal syndrome that had limited consequences on operant responses for food and induced place aversion. These effects were associated with morphine-induced changes in the expression of CB1 receptor mRNA in specific nuclei of the reward circuit, including dorsal caudate putamen, nucleus accumbens, and septum. Additionally, the opioid antagonist naloxone precipitated a mild cannabinoid-like withdrawal syndrome in cannabinoid-dependent rats and blocked cannabinoid self-administration in mice. Neither SR141716A nor naloxone produced any intrinsic effect on these behavioral models. The present results show the existence of a cross-interaction between opioid and cannabinoid systems in behavioral responses related to addiction and open new strategies for the treatment of opiate dependence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438610      PMCID: PMC6762870     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  60 in total

1.  Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.

Authors:  T Rubino; P Massi; D Viganò; D Fuzio; D Parolaro
Journal:  Life Sci       Date:  2000-04-21       Impact factor: 5.037

2.  Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol.

Authors:  B Hine; E Friedman; M Torrelio; S Gershon
Journal:  Science       Date:  1975-02-07       Impact factor: 47.728

3.  A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.

Authors:  D J Mason; J Lowe; S P Welch
Journal:  Eur J Pharmacol       Date:  1999-09-24       Impact factor: 4.432

4.  Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice.

Authors:  M S Mascia; M C Obinu; C Ledent; M Parmentier; G A Böhme; A Imperato; W Fratta
Journal:  Eur J Pharmacol       Date:  1999-11-03       Impact factor: 4.432

5.  Absence of opiate rewarding effects in mice lacking dopamine D2 receptors.

Authors:  R Maldonado; A Saiardi; O Valverde; T A Samad; B P Roques; E Borrelli
Journal:  Nature       Date:  1997-08-07       Impact factor: 49.962

6.  Cannabinoid receptor gene (CNR1): association with i.v. drug use.

Authors:  D E Comings; D Muhleman; R Gade; P Johnson; R Verde; G Saucier; J MacMurray
Journal:  Mol Psychiatry       Date:  1997-03       Impact factor: 15.992

7.  Localization of cannabinoid receptor mRNA in rat brain.

Authors:  L A Matsuda; T I Bonner; S J Lolait
Journal:  J Comp Neurol       Date:  1993-01-22       Impact factor: 3.215

8.  Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.

Authors:  G Pugh; D J Mason; V Combs; S P Welch
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

9.  The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference.

Authors:  F Rodríguez De Fonseca; P Rubio; J L Martín-Calderón; S B Caine; G F Koob; M Navarro
Journal:  Eur J Pharmacol       Date:  1995-02-14       Impact factor: 4.432

10.  Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine.

Authors:  G Vela; M Ruiz-Gayo; J A Fuentes
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

View more
  118 in total

1.  Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.

Authors:  Marek Zubrzycki; Anna Janecka; Andreas Liebold; Mechthild Ziegler; Maria Zubrzycka
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  Comparative effects of pulmonary and parenteral Δ⁹-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats.

Authors:  Laurie A Manwell; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2014-11-15       Impact factor: 4.530

3.  Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.

Authors:  L Fattore; Ms Spano; V Melis; P Fadda; W Fratta
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Is cannabinoid transmission involved in rewarding properties of drugs of abuse?

Authors:  Daniela Parolaro; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

Authors:  Anna Castañé; Rafael Maldonado; Olga Valverde
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

Review 6.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 7.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

8.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

9.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

10.  CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.

Authors:  Kiri L Wills; Kiran Vemuri; Alana Kalmar; Alan Lee; Cheryl L Limebeer; Alexandros Makriyannis; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2014-04-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.